BioCryst Pharmaceuticals
BCRX
BCRX
258 hedge funds and large institutions have $1.26B invested in BioCryst Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 79 increasing their positions, 90 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
4% less capital invested
Capital invested by funds: $1.31B → $1.26B (-$49.8M)
2.43% less ownership
Funds ownership: 83.37% → 80.95% (-2.4%)
12% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 90
Holders
258
Holding in Top 10
5
Calls
$12.1M
Puts
$8.5M
Top Buyers
| 1 | +$11.9M | |
| 2 | +$10.9M | |
| 3 | +$8.87M | |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$4.07M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.98M |
Top Sellers
| 1 | -$16M | |
| 2 | -$10.5M | |
| 3 | -$10.2M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.11M |
| 5 |
Goldman Sachs
New York
|
-$7.74M |